[144] Travere Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Travere Therapeutics, Inc. (TVTX) reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $250,000.00. The filing states the shares were acquired and will be sold on 09/22/2025 via a stock option exercise from the issuer, with payment in cash. The issuer's outstanding shares are listed as 89,138,673. The filer reports no securities sold in the past three months. Several identifying fields (filer CIK and contact details) are blank in the provided text.

Positive

• Transaction is fully documented with acquisition date, sale date, broker, payment method, and aggregate value provided
• No securities sold in prior three months, as explicitly reported

Negative

• Filer identification fields are incomplete or blank in the provided text (CIK and contact details missing), limiting verification from this extract

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice for disposition of option-exercised shares; documentation shows cash payment and brokered sale.

The filing documents a proposed sale under Rule 144 of 10,000 common shares acquired by stock option exercise and intended for sale the same day through Morgan Stanley Smith Barney LLC on NASDAQ. The filing includes the aggregate market value and the issuer's total outstanding shares, and it states there were no sales in the prior three months. Some filer identification fields in the supplied extract are blank, which limits verification from this text alone.

Equity Research Analyst

TL;DR: Small, clearly identified sale; no recent disposals reported and proceeds will be cash-settled through a broker.

The notice indicates a single proposed disposition of 10,000 shares valued at $250,000, acquired and to be sold on 09/22/2025 via stock option exercise with cash payment. The statement that nothing was sold in the prior three months is included. From an equity perspective within this filing, the detail is transactional and does not present operational or financial results.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10000	250000.00	89138673	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/22/2025	Stock Option Exercise	Issuer			10000	09/22/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Travere Therapeutics' (TVTX) Form 144 report?

The Form 144 reports a proposed sale of 10,000 common shares valued at $250,000, to be sold on 09/22/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the shares acquired for the TVTX Form 144 filing?

The shares were acquired on 09/22/2025 via a stock option exercise from the issuer, with payment in cash.

Does the filing show any prior sales by the same person in the past three months?

The filing states "Nothing to Report" under securities sold during the past three months.

Which broker is handling the proposed sale in the Form 144?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

What is the issuer's outstanding share count listed in the filing?

The filing lists 89,138,673 shares outstanding.